Nimble, smart, and staying ahead. Argus has identified six companies that we believe should be added to our Innovation theme model portfolio. These are companies we know well (which we like) and that continue to perform well and demonstrate financial stability and success. Over and over again, they nurture their innovative mindset, responding to market needs and trends, remaining nimble, and adapting to stay ahead. Our team of analysts regularly review and analyze growth trends, business models, and management strategies, and we have 30 stocks in this portfolio. We break the theme into four categories of innovation: First to Market; New Product Specialists; Product and Process Perfectors; and Industry Disruptors. We enjoy throwing ourselves into this theme as we continue to learn about new technologies and discoveries. Below are the six companies recently added to our portfolio. All are rated BUY at Argus. To see the complete list of companies in the portfolio, please see the Theme Portfolios section of the Argus website. Note that these model strategies can be licensed for direct money management.

Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for spinal muscular atrophy and AD. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,605 people, and is a component of the S&P 500.

The iShares 20+ Year Treasury Bond ETF (TLT) remains in a bear channel off the peaks since September. On Wednesday, TLT gapped higher after the CPI report, with above-average volume. Daily momentum has been in oversold territory for a big part of the past three months. The first key upside level to overcome is at $87.50, the lows from April 2024. The next piece of chart resistance lies at $89.50, the September lows. On the downside, a break of the recent lows at $85 opens the door for an important test of the lows from October 2023. Market sentiment from the two- to 10-year remains bearish, fund flows have been negative but not heavy enough to be bullish and signal panic, and the Commitment of Traders (COT) data is less bullish. Still, when the COT data got less bullish in April through June 2024, bond prices rallied. The iShares Silver Trust (SLV) completed a small head-and-shoulders pattern on December 18, but saw little downside follow-through (a positive sign). It's possible that the formation since the peak on October 22 was a bullish, three-wave, ABC decline. SLV has rallied above the low from late November, creating a bullish false breakdown. In addition, the ETF has busted above the bearish trendline off the October peaks -- but not by a lot. Fibonacci retracement levels come in at $28.30, $29, and $29.70, while chart resistance is between $29 and $29.50. The lows down near $26 are short-term support. Meanwhile, the COT data remains bearish for GLD (SPDR Gold Shares), but has improved for SLV. Some sentiment data is quite bearish, while other indicators are neutral. Seasonality is much better in the beginning of the year. (Mark Arbeter, CMT)

OSI SYSTEMS INC has an Investment Rating of HOLD; a target price of $166.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.